Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical
features, with α-synuclein pathology as the gold standard to establish the definitive …

Neurodegenerative diseases are a common cause of morbidity and cognitive impairment in
older adults. Most clinicians who care for the elderly are not trained to diagnose these …

Dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD), although
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …

The Parkinson's disease (PD) research field has seen the advent of several promising
biomarkers and a deeper understanding of the clinical features of the disease from the …

Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The
recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the …

Abstract α-Synuclein is an abundantly expressed neuronal protein that is at the center of
focus in understanding a group of neurodegenerative disorders called α-synucleinopathies …

Parkinson's disease (PD) and atypical Parkinsonian syndromes are progressive
heterogeneous neurodegenerative diseases that share clinical characteristic of …

Two centuries ago in 1817, James Parkinson provided the first medical description of
Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to …

The broad importance of dementia is undisputed, with Alzheimer's disease justifiably getting
the most attention. However, dementia with Lewy bodies and Parkinson's disease dementia …

In Alzheimer disease (AD), which is the most common cause of dementia, the underlying
disease pathology most probably precedes the onset of cognitive symptoms by many years …